| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: Capio BioSciences |
| Recipient: An Immediate Family Member |
| Company: Archimmune Therapeutics |
| Recipient: An Immediate Family Member |
|
| Stock and Other Ownership Interests |
| Company: Capio Biosciences |
| Recipient: An Immediate Family Member |
| Company: Archimmune Therapeutics |
| Recipient: An Immediate Family Member |
| Company: Nanorobotics |
| Recipient: An Immediate Family Member |
|
| Honoraria |
| Company: MJH Life Sciences |
| Recipient: You |
| Company: Aptitude Health |
| Recipient: You |
| Company: Curio Science |
| Recipient: You |
| Company: Peerview |
| Recipient: You |
| Company: Clinical Care Options |
| Recipient: You |
| Company: Mashup Media |
| Recipient: You |
| Company: Dava Oncology |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Exelixis |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Aravive |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Eli Lilly |
| Recipient: You |
| Company: AVEO |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Sanofi/Aventis |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Loxo/Lilly |
| Recipient: You |
| Company: Xencor |
| Recipient: You |
| Company: Johnson & Johnson/Janssen |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: OncoC4 |
| Recipient: You |
| Company: Loxo/Lilly |
| Recipient: Your Institution |
| Company: Tempus |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: ALX Oncology |
| Recipient: Your Institution |
| Company: Exelixis |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Janux Therapeutics |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Circulating tumor cell novel capture by c-MET technology |
| Recipient: Your Institution |
| Please describe: Prochelators as Targeted Prodrugs for Prostate Cancer |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Bayer |
| Recipient: You |
|
| Other Relationship |
| Company: ASCO |
| Recipient: You |
| Company: KCA |
| Recipient: You |
| Company: KidneyCan |
| Recipient: You |
| Company: Myrovlytis Trust |
| Recipient: You |
| Company: Winn Foundation |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|